The authors noticed that the previous lack of response to eltrombopag may predict a lack of response to avatrombopag; however, this observation has not been confirmed in the larger retrospective observational study that evaluated the switch from a TPO-RA to avatrombopag in 44 patients with primary and secondary ITP [15]. This evidence concerns the gene TPO and autoimmune thrombocytopenic purpura.